NDAORALTABLET
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
TRICOR (fenofibrate) by AbbVie is peroxisome proliferator-activated receptor alpha agonists [moa]. Approved for hypertriglyceridemia, dyslipidemia, hypercholesterolemia and 1 more indications. First approved in 2004.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRICOR (fenofibrate) is an oral small-molecule fibrate approved in 2004 that works as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist. It treats hypertriglyceridemia, dyslipidemia, and mixed hyperlipidemia by reducing triglycerides and improving lipid profiles. The drug also has off-label use in metabolic syndrome, diabetic retinopathy, and nonalcoholic fatty liver disease.
$136KPart D
LOE ApproachingDeclining
With lifecycle approaching loss of exclusivity and minimal Part D spending, the brand team is likely in defensive mode with constrained headcount and focus on cost optimization.
Mechanism of Action
Peroxisome Proliferator-activated Receptor alpha Agonists
Pharmacologic Class:
Peroxisome Proliferator Receptor alpha Agonist
Indications (4)
Worked on TRICOR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.